Trials
1 active
1 in total · 1 in the EU
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Two capsules of NB-4746 will be administered twice daily (dose will be defined after Ph 1b data is reviewed).”In the company’s words, NCT07369076 on ClinicalTrials.gov
- Tested for
- Amyotrophic Lateral Sclerosis (ALS)
- Main trialPhase 1/2
- “The purpose of this trial is to learn about the effects of NB-4746 compared with placebo in people with amyotrophic lateral sclerosis. The questions this trial aims to answer in comparing NB-4746 to placebo are: * What adverse events associated with taking NB-4746 are reported during this trial? (An adverse event is any sign or symptom that participants have during a trial. Adverse events may or may not be caused by treatments in the trial.) * How does NB-4746 move into, through, and out of the body of the participants? * What is the change in the level of neurofilament light (NfL) in the…”In the company’s words, NCT07369076 on ClinicalTrials.gov
Other drugs for Amyotrophic Lateral Sclerosis (ALS)
Coming up1
- Apr 2027Phase 1/2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1/2Recruiting | Apr 2027 | A Clinical Trial to Evaluate NB-4746 in Participants With Amyotrophic Lateral Sclerosis. |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026